Epoetin alfa biosimilar (Apotex)

阿法依伯汀生物类似药 (Apotex)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEpoetin alfa biosimilar (Apotex)
Drug Alias Name阿法依伯汀生物仿制药 (Apotex)APO-EPO
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesApotex
China Registration ClassN/A

Develop Information

Active CompaniesApotex
Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A